I think the FDA is just looking for production of dystrophin in a larger group for approval of this drug ,Sarepta has hired a third party for exact measuring ,Natural history has already proven dystrophin production slows the progression of dmd .
So my thinking is after 24 weeks of dosing the FDA will approve the drug here..''confirmation of dystrophin''
For ramp up and production ..It is simply a wise choice.
ebola has a non death rate of of 40 percent in healthy humans and i do not think zmapp is all that ,we will see in the African trials
Oppenheimer Maintains Outperform On Sarepta As 3-Year Data Support Eteplirsen’s Clinical Benefit
October 14, 2014 12:01 PM EDT by Editor Corey Williams in Exclusively Published, Healthcare
In a research report issued Tuesday, Oppenheimer analyst Christopher Marai maintained an Outperform rating on Sarepta Therapeutics (NASDAQ:SRPT) with a $45 price target, as longer term follow-up presented at World Muscle Society (WMS) for SRPT’s eteplirsen’s phase 2b data highlights improved function vs. natural history.
Marai noted, “Newly published nat history data at WMS highlight eteplirsen’s benefit even in the ITT population (including 2 patients who became non-ambulatory). Data demonstrated a clinically meaningful 27-31m benefit (-111m vs -138-142m) (Pane et al.). In the mITT population, the benefit looks significantly better even with recent declines. We continue to expect accelerated approval of eteplirsen given the unmet need, preliminary evidence of efficacy and minimal toxicity that looks better than current standard of care steroids. Recall, a majority of DMD patients receive steroids, that, while not approved, delay disease progression but have side effects.”
It is no other treatments that can hold a candle to gild .you got to be a bad researcher to see anything negative here.
You are wrong about that , i am mostly in for long term and will be happy to buy at discount prices ..
Mostly all at lows ......sarepta under valued by 20 points as of now ..
The USAID Development Innovation Accelerator BAA for Fighting Ebola: A Grand Challenge for Development
Solicitation Number: BAA-EBOLA-2014
Agency: Agency for International Development
Office: Washington D.C.